Ras Pull-down Activation Assay Biochem Kit (bead pull-down format) - 20 Assays

Ras Activation Assay Biochem Kit (bead pull-down format) - 20 Assays
$0.00

Product Uses Include

  • Analysis of in vivo Ras activation.

      Introduction
      The Ras switch operates by alternating between an active, GTP-bound state and an inactive, GDP-bound state.  Understanding the mechanisms that regulate activation / inactivation of Ras-like GTPases is of obvious biological significance and is a subject of intense investigation.  The fact that Ras family effector proteins will specifically recognize the GTP bound form of the protein has been exploited experimentally to develop a powerful affinity purification assay that monitors Ras protein activation.  The assay uses the Ras-binding domain (RBD) of the Ras effector kinase Raf1.  The Raf-RBD domain has been shown to bind specifically to the GTP-bound form of Ras proteins.  The fact that the Raf-RBD has a high affinity for GTP-Ras and that its binding results in a significantly reduced intrinsic and catalytic rate of hydrolysis of Ras make it an ideal tool for affinity purification of GTP-Ras from cell lysates.  The Raf-RBD is in the form of a GST fusion protein, which allows one to "pull-down" the Raf-RBD/GTP-Ras complex with glutathione affinity beads.  The assay therefore provides a simple means of quantitating Ras activation in cells.  The amount of activated Ras is determined by a western blot using a Ras specific antibody.

      Kit contents
      The kit contains sufficient materials for 20 assays, depending on assay setup, and includes reagents for positive and negative controls.  A larger 50 assay version of this kit is available as Cat. # BK008. The following components are included:

      1. GST tagged Raf1-RBD protein bound to colored glutathione agarose beads (Cat. # RF02).
      2. p21 Ras monoclonal antibody
      3. Cell lysis Buffer
      4. Protease inhibitor cocktail (Cat. # PIC02)
      5. Wash Buffer
      6. Loading Buffer
      7. STOP Buffer
      8. GTPγS (non-hydrolyzable GTP analog, Cat. # BS01)
      9. GDP
      10. Manual with detailed protocols and extensive troubleshooting guide.
      beads

      Figure 1. The brightly colored glutathione agarose beads in kit BK008-S makes the kit easy to use.

      Equipment needed

      1. SDS-PAGE minigel system and western blotting transfer apparatus

      Associated Products:

      G-LISA Products:
      Rac1 G-LISA™ Activation Assay, luminescence format (Cat.# BK126)
      Rac1,2,3 G-LISA™ Activation Assay, colorimetric format (Cat.# BK125)
      RhoA G-LISA™ Activation Assay, colorimetric format (Cat.# BK124)
      RhoA G-LISA™ Activation Assay, luminescence format (Cat.# BK121)
      Cdc42 G-LISA™ Activation Assay, colorimetric format (Cat.# BK127)

      Associated Products:
      Anti-Cdc42 monoclonal antibody (Cat.# ACD03)
      Anti-Rac1 monoclonal antibody (Cat.# ARC03)
      Anti-RhoA monoclonal antibody (Cat.# ARH03)

      For product Datasheets and MSDSs please click on the PDF links below.   For additional information, click on the FAQs tab above or contact our Technical Support department at tservice@cytoskeleton.com

      AuthorTitleJournalYearArticle Link
      Kirolos, Sara A. et al.A chemorepellent inhibits local Ras activation to inhibit pseudopod formation to bias cell movement away from the chemorepellentMolecular biology of the cell2022ISSN 1939-4586
      Jeon, S M et al.Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activationInternational Journal of …2022Article Link
      Ablain, Julien et al.SPRED1 deletion confers resistance to MAPK inhibition in melanomaThe Journal of experimental medicine2021ISSN 1540-9538
      Wiley, Christopher D. et al.Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysisCell Metabolism2021ISSN 1932-7420
      Tulpule, Asmin et al.Kinase-mediated RAS signaling via membraneless cytoplasmic protein granulesCell2021ISSN 1097-4172
      Yan, Wupeng et al.Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFRCell Reports2020ISSN 2211-1247
      Hood, Fiona E. et al.Isoform-specific Ras signaling is growth factor dependentMolecular Biology of the Cell2019ISSN 1939-4586
      Cai, Diana et al.Identification and characterization of oncogenic SOS1 mutations in lung adenocarcinomaMolecular Cancer Research2019ISSN 1557-3125
      Cocco, Emiliano et al.Resistance to TRK inhibition mediated by convergent MAPK pathway activationNature Medicine2019ISSN 1546-170X
      Rijal, Ramesh et al.An endogenous chemorepellent directs cell movement by inhibiting pseudopods at one side of cellsMolecular Biology of the Cell2019ISSN 1939-4586
      Pilling, Darrell et al.Different Isoforms of the Neuronal Guidance Molecule Slit2 Directly Cause Chemoattraction or Chemorepulsion of Human NeutrophilsThe Journal of Immunology2019ISSN 0022--1767
      Brandt, Raphael et al.Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epitheliumNature Communications2019ISSN 2041-1723
      Dardaei, Leila et al.SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsNature Medicine2018ISSN 1546-170X
      Saikia, Minakshi et al.Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesylation of RasOncotarget2018ISSN 1949-2553
      Smolkin, Tatyana et al.Complexes of plexin-A4 and plexin-D1 convey semaphorin-3C signals to induce cytoskeletal collapse in the absence of neuropilinsJournal of Cell Science2018ISSN 1477-9137
      Whiteside, Theresa L.Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomesTranslational Cancer Research2017ISSN 2219-6803
      Malchers, Florian et al.Mechanisms of primary drug resistance in FGFR1-amplified lung cancerClinical Cancer Research2017ISSN 1557-3265
      Lu, Xinyuan et al.MET exon 14 mutation encodes an actionable therapeutic target in lung adenocarcinomaCancer Research2017ISSN 1538-7445
      Walton, Josephine B. et al.CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivityScientific Reports2017ISSN 2045-2322
      Ilinskaya, Olga N. et al.Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase)Biochimica et Biophysica Acta - Molecular Cell Research2016ISSN 1879-2596
      Hrustanovic, Gorjan et al.RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancerNature Medicine2015ISSN 1546-170X
      Larribere, Lionel et al.NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based modelPigment Cell and Melanoma Research2015ISSN 1755-148X
      Du, Chang Qing et al.Inhibition of farnesyl pyrophosphate synthase prevents norepinephrine- induced fibrotic responses in vascular smooth muscle cells from spontaneously hypertensive ratsHypertension Research2014ISSN 0916-9636
      Yan, Chao et al.Discovery and characterization of small molecules that target the GTPase Ral2014ISSN 1476--4687
      Ciaglia, Elena et al.N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulationJournal of Leukocyte Biology2013ISSN 1938--3673
      Stoppa, Giovanna et al.Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cellsApoptosis : an international journal on programmed cell death2012ISSN 1573--675X
      Kern, F. et al.Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesisOncogene 2013 32:192012ISSN 1476--5594
      Kowluru, Renu A.Role of Matrix Metalloproteinase-9 in the Development of Diabetic Retinopathy and Its Regulation by H-RasInvestigative Ophthalmology & Visual Science2010ISSN 0146-0404
      Jiang, Xiao Sheng et al.Activation of Rho GTPases in Smith-Lemli-Opitz syndrome: pathophysiological and clinical implicationsHuman molecular genetics2010ISSN 1460--2083
      Rose, A. et al.Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cellsBritish Journal of Pharmacology2010ISSN 0007-1188
      Lito, Piro et al.Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblastsThe Journal of biological chemistry2008ISSN 0021--9258
      Wasylyk, Christine et al.Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubulesCancer Research2008ISSN 0008-5472
      Wang, J. X. et al.Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferationBritish Journal of Pharmacology2007ISSN 0007-1188

       

      Question 1: I have high background and/or multiple bands on my western blot.  How can I fix this?

      Answer 1:  There are multiple causes of high background and/or multiple bands.  Some suggestions to improve background signal include:

      1. When blotting use 70v for 45min only as the small G-proteins are very mobile.
      2. Fully remove SDS from the gel by using a non-SDS containing buffer for transfer and performing a full 15 min gel wash step in the transfer buffer before blotting.
      3. Dry the PVDF membrane for 30 min after transfer and before blocking (not necessary for nitrocellulose)
      4. Making sure that the TBST contains 10 mM Tris, 0.05% Tween 20 and 150 mM NaCl.
      5. Incubating with the primary antibody overnight at 4°C and using the appropriate ECL detection system. 

       

      Question 2: How much of the beads should I use for my pull-down experiments?

      Answer 2:  Raf-RBD beads (Cat. # RF02) will bind to Ras-GDP with a much lower affinity than Ras-GTP.  If too many Raf-RBD beads are added to the pull-down assay there will be significant binding to inactive (GDP-bound) Ras. The result of this will be an underestimation of Ras activation.  For this reason, we highly recommend performing a bead titration to determine optimal conditions for any given Ras activation or inactivation assay.  Once optimal conditions have been established, bead titrations should no longer be necessary. We recommend 20, 40 and 60 μl (66, 132 and 198 µg) bead titrations.

       

      Question 3:  How can I test whether the beads are working properly?

      Answer 3:  A standard biological assay for Raf-RBD beads consists of a Ras protein pull-down from cells loaded with either GTPγS (Cat. # BS01) or GDP.  Here are guidelines to follow (see Cat. # RF02 or BK008 datasheets for more details):

       

      Positive Cellular Protein Control:

      Total cell lysate (200 – 500 µg) should be loaded with GTPγS as a positive control for the pull-down assay. The following reaction details how to load endogenous Ras with the nonhydrolysable GTP analog (GTPγS).  This is an excellent substrate for Raf-RBD beads and should result in a strong positive signal in a pull-down assay.

      a)  Perform GTP loading on 200 – 500 μg of cell lysate that is at a protein concentration between 0.4 – 2.0 mg/ml  by adding 1/10th volume of Loading Buffer.

      b)  Immediately add 1/100th volume of GTPγS (200 μM final concentration). Under these conditions, 5 - 10% of the Ras protein will load with non-hydrolysable GTPγS and will be “pulled-down” with the Raf-RBD beads in the assay.

      c)  Incubate the control sample at 37°C for 30 minutes with gentle rotation.

      d)  Stop the reaction by transferring the tube to 4°C and adding 1/10th volume of STOP Buffer.

      e)  Use this sample in a pull-down assay immediately.

       

      Negative Cellular Protein Control:

      This reaction should be performed in an identical manner to the Positive Control reaction except that 1/100th volume of GDP (1 mM final concentration) should be added to the reaction in place of the GTPγS. Loading endogenous Ras with GDP will inactivate Ras and this will bind very poorly to Raf-RBD beads.

       

       

       

      If you have any questions concerning this product, please contact our Technical Service department at tservice@cytoskeleton.com